A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).

Sagar Lonial,Albert Oriol,Maria-Victoria Mateos,Paula Rodriguez-Otero,Nizar J. Bahlis,William Bensinger,Kimmo Porkka,Niels W.C.J. van de Donk,Wai Yiu,Carl Di Casoli,Annette Ervin-Haynes,Mohamed H. Zaki,Annette Juul Vangsted

A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).

2017

Sagar Lonial
Albert Oriol
Maria-Victoria Mateos
Paula Rodriguez-Otero
Nizar J. Bahlis
William Bensinger
Kimmo Porkka
Niels W.C.J. van de Donk
Wai Yiu
Carl Di Casoli
Annette Ervin-Haynes
Mohamed H. Zaki
Annette Juul Vangsted

TPS8055Background: LEN + DEX (Rd) is approved for pts with newly diagnosed MM, including those who are transplant non-eligible (TNE). DURVA is a monoclonal antibody to programmed death ligand 1 (PD...

Keywords:

Dexamethasone
Physical therapy
Lenalidomide
Cancer research
Durvalumab
Medicine
Multiple myeloma
newly diagnosed
in patient
Oncology
Internal medicine
programmed death
Monoclonal antibody
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations